We treated 26 frozen shoulders in 26 cases separated into two groups by arthroscopic capsular release. Group A comprised 14 patients (male 7, female 7) with an average age of 53.7 (34-78) who underwent arthroscopic subacromial decompression (ASD). Group B consisted of 12 cases (male 5, female 7) with an average age of 58.2 (41-78) who were treated without ASD. The mean follow-up period was 14 (12-16) months. We compared the range of motion in the effected shoulders and the Japan Orthopaedic Association (JOA) scores between the two groups. We also investigated any improvement of ROM one month after operation in regards to rehabilitation being performed 3 times or under 2 times per week in order to acquire a greater ROM of external rotation. Group A led group B significantly with superior clinical results including ROM and JOA scores. Furthermore, rehabilitation administered 3 times per week increased the ROM of the shoulder after one month of operation. Therefore, it was found that in arthroscopic capsular release of frozen shoulder, additional treatment with ASD and frequent rehabilitation with ROM exercises for external rotation yielded clinical improvement in frozen shoulder outcomes.

View full abstract

Genetic polymorphisms in the cytochrome P450 family are widely known to contribute to inter-individual differences in drug pharmacokinetics. In this study we report a case of a patient with cytochrome P450 2C19 polymorphism. A 57-year-old woman presented with right cerebral hemorrhage and left hemiplegia. She was administrated phenytoin (200 mg/day)and phenobarbital (60 mg/day) to prevent convulsions. After a change in phenytoin dosage (97% grains to 10% grains), she developed ataxia and experienced a disturbance in her activities of daily living. She was admitted to our hospital. Her serum concentration of phenytoin was found to be at a toxic level (45.9μg/ml) and serum phenobarbital was relatively high (19.1μg/ml). She showed an extremely low clearance of phenytoin, so we checked the genotype of her P450 2C9 and P450 2C19 cytochromes, which are metabolic enzymes of phenytoin. For cytochrome P450 2C9, the patient was a homozygous extensive metabolizer (wild type, *1/*1), but for cytochrome P450 2C19, she was a poor metabolizer (*3/*3). Her phenytoin dosage was reduced, and her ataxia, activities of daily living, left hemiplegia, and cerebral blood flow in Xe-CT improved.

View full abstract

Evidence based Medicine for Physical Therapy and Management of Cerebral Palsy…Yoshimi ASAGAI 571

Report and Proposal of the Rehabilitation-guideline Committee on Cerebral Palsy…Toshiro OKAGAWA 575

Evaluation Guideline for Children with Cerebral Palsy…Izumi KONDO 582

Establishing Cerebral Palsy Rehabilitation—Management of Spasticity—…Hidetoshi TAKAHASHI, Youko KOMUNE 588

View full abstract